A phase I, double-blind, randomized study to evaluate the safety and immunogenicity of a new Meningococcal A Conjugate vaccine versus a Meningococcal Polysaccharide A+C reference vaccine and a Tetanus Toxoid control vaccine, given as single intramuscular injections in healthy adults from 18 to 35 years of age (India)

INTERVENTION: Single intramuscular injection of one of the following: 1. Study vaccine group: Serum Institute of India Limited (SIIL) PsA‐TT (Meningococcal A Polysaccharide conjugated to Tetanus Toxoid) 2. Reference vaccine group: Sanofi Pasteur Meningococcal Polysaccharide Vaccine A+C 3. Control vaccine group: Serum Institute of India Limited (SIIL) Tetanus Toxoid (Adsorbed) IP CONDITION: Meningococcal disease ; Infections and Infestations ; Meningococcal disease PRIMARY OUTCOME: Incidence of adverse events including solicited adverse events and laboratory abnormalities over 4 weeks post‐vaccination SECONDARY OUTCOME: 1. Descriptive assessment of the immune response 4 weeks post‐vaccination in terms of serum bactericidal activity using baby rabbit complement (SBA/BRC) and anti‐PsA IgG response; 2. Descriptive assessment of the persistence of an immune response 24 and 48 weeks post‐vaccination in terms of SBA/BRC and anti‐PsA IgG response INCLUSION CRITERIA: Healthy adults between 18 and 35 years of age